NEOK Bio

News

Braveheart, AAVantgarde rounds head recent biofinancings

Our latest crop of biotech financings has nine-figure rounds for Braveheart and AAVantgarde, with Azalea Therapeutics and NEOK Bio also raising funds.

News

Sanofi pays $180m for rights to Kali autoimmune drug

Sanofi has licensed rights to Kali's trispecific T-cell engager KT501, in trials for rheumatoid arthritis, in a deal valued at nearly $1.2bn.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks